Dr. Reddy’s gets OK to market generic allergy drug
HYDERABAD, India — A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.
Dr. Reddy’s said the U.S. District Court of New Jersey had filed a stipulation and order lifting the earlier injunction against the drug maker regarding the selling of a version of fexofenadine hydrochloride and pseudoephedrine hydrochloride tablets in the 180-mg/240-mg strength. The drug is a generic version of Sanofi-Aventis’ and Albany Molecular Research’s Allegra-D 24.
Sanofi and Albany Molecular Research had filed suit against Dr. Reddy’s, alleging patent infringement. In June 2010, the court granted the two companies an injunction preventing Dr. Reddy’s from selling its version of the drug.
Report: Pa. officials may limit Rx transfers among patients
NEW YORK — Fears about the likelihood of medication errors have officials in Pennsylvania mulling the possibility of restrictions on patients transferring prescriptions from one pharmacy to another, according to published reports.
CNBC reported Sunday that a rule recently put in place by the Ohio Board of Pharmacy that allows only one transfer per year had inspired Pennsylvania officials to consider a similar rule for their own state.
Officials said frequent transfers can result in confusion between pharmacists and patients that could lead to medication errors, especially because those transfers often are made over the phone, according to the article.
Retail pharmacies frequently offer such incentives as gift cards and discounts to customers who transfer their prescriptions or who encourage others to do the same.
Novartis’ Menveo approved for use in children
BASEL, Switzerland — The Food and Drug Administration has approved a Novartis vaccine for preventing meningococcal disease in children, the Swiss drug maker said.
Novartis announced the approval of Menveo (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) for active immunization to prevent certain forms of meningococcal disease caused by Neisseria meningitidis in children ages 2 to 10 years. The FDA approved the vaccine last year for use in adolescents and adults ages 11 to 55 years.
“The approval of Menveo for the use in children 2 to 10 years of age is another important step toward our goal to protect people of all ages against this devastating disease,” Novartis vaccines and diagnostics division head, Andrin Oswald, said.